Advertisement

International Urology and Nephrology

, Volume 36, Issue 3, pp 417–423 | Cite as

Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma

  • Attalla Farag El-kott
  • Abdalla Mohamed Khalil
  • Ayman EL-Meghawry EL-Kenawy
Article

Abstract

Background: The authors found previously that plasma levels of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) were elevated in patients with bladder carcinoma and were associated with features of biologically aggressive disease. The present study has been performed to analyze the expressions of two antigens by immunohistochemical staining in bladder transitional cell carcinoma. Patients and methods: The tumors from 72 men and 28 women with a mean age 46.15 years (range 30–67 years) were examined. Paraffin sections of 5 μm thickness were prepared for immunohistochemical staining of uPA and uPAR antigens. Age, sex, tumor grade and stage, DNA ploidy, lymph node status, and metastases were evaluated in relation to outcome. Univariate and multivariate analysis of survival were performed. Results: The overall 5-year survival was 66%. Thirty six and 46 cases were positive for uPA and uPAR expressions, respectively. In univariate analysis, tumor stage, lymph node status, metastases, uPA and uPAR have a significant impact on the survival for these patients. In a Cox proportional hazard model, uPAR sustained its significant impact on survival. Conclusions: These findings suggest that uPAR is an independent additional prognostic factor in patients with transitional cell carcinoma of the bladder.

Keywords

Bladder cancer Immunohistochemistry survival uPA uPAR 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Greenlee, RT, Hill-Harmon, MB, Murray, T,  et al. 2001Cancer statistics.CA Cancer J Clin511536PubMedGoogle Scholar
  2. Brown, FM 2000Urine cytology.It is still the gold standard for screening? Urol Clin North Am272537Google Scholar
  3. Murphy, WM, Soloway, MS, Jukkola, AF,  et al. 1984Urinary cytology and bladder cancer.The cellular features of transitional cell neoplasms. Cancer5315551565Google Scholar
  4. Lokeshwar, VB, Soloway, MS 2001Current bladder tumor tests: does their projected utility fulfill clinical necessity?J Urol16510671077Google Scholar
  5. Ozen, H, Hall, MC 2000Bladder cancer.Curr Opin Oncol12255259Google Scholar
  6. Conese, M, Blasi, F 1995The urokinase/urokinasereceptor system and cancer invasion.Baillieres Clin Haematol8365389Google Scholar
  7. Ellis, V, Dano, K 1992The urokinase receptor and the regulation of cell surface plasminogen activation.Fibrynolysis6(Suppl. 4)2734Google Scholar
  8. Dano, K, Behrendt, N, Brunner, N,  et al. 1994The urokinase receptor.Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis8189203Google Scholar
  9. Nykjaer A. The urokinase receptor: an activation antigen in T cells. Univ of Arrhus 1995; 1–110.Google Scholar
  10. Paysant, J, Vasse, M, Soria, J,  et al. 1998Regulation of the uPA/uPAR system expressed on monocytes by the deactivating cytokines, IL-4, IL-10 and IL-13: consequences on cell adhesion to vitronectin and fibrinogen.Br J Haematol1004551Google Scholar
  11. Choong, PFM, Ferno, M, Akerman, M,  et al. 1996Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas.IntJ Cane69268272Google Scholar
  12. Hasui, Y, Marutsuka, K, Nishi, S,  et al. 1994The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer.J Urol1511619discussion 19–20Google Scholar
  13. Cajot, JF, Kruithof, EK, Schleuning, WD,  et al. 1986Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines.Int J Cancer38719727Google Scholar
  14. Grondahl-Hansen, J, Christensen, IJ, Rosenquist, C,  et al. 1993High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cystolic extracts of breast carcinomas are associated with poor prognosis.Cancer Res5325132521Google Scholar
  15. Mueller, BM, Yu, YB, Laug, WE 1995Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice.Proc Natl Acad Sci USA92205209Google Scholar
  16. Cubellis, MV, Wun, TC, Blasi, F 1990Receptormediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.EMBO J910791085Google Scholar
  17. Blasi, F 1993Urokinase and urokinase receptor: a paracrine/autocrine system regulating cells migration and invasiveness.Bioessays15105111PubMedGoogle Scholar
  18. Mignatti, P, Rifkin, DB 1993Biology and biochemistry of proteinases in tumor invasion.Physiol Rev73161195Google Scholar
  19. Mizukami, IF, Garni-Wagner, BA, DeAngelo, LM,  et al. 1994Immunologic detection of the cellular receptor for the urokinase plasminogen activatorClin Immunol Immunopathol7196104Google Scholar
  20. Pyke, C, Ralfkiaer, E, Ronne, E,  et al. 1994Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer.Histopathology24131138Google Scholar
  21. Pepper, MS, Sappino, AP, Stocklin, R,  et al. 1993Upregulation of urokinase receptor expression on migrating endothelial cells.J Cell Biol122673684Google Scholar
  22. Stahl, A, Mueller, BM 1994Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.Cancer Res5430663071Google Scholar
  23. Hisazumi, H, Andersson, L, Collins, VP 1977Fibrinolytic activity of in vitro cultivated human bladder cell lines.Urol Res5133139Google Scholar
  24. Dubeau, L, Jones, PA, Rideout, WM 3III,  et al. 1988Differential regulation of plasminogen activators by epidermal growth factor in normal and neoplastic human urothelium.Cancer Res4855525556Google Scholar
  25. Hasui, Y, Suzumiya, J, Marutsuka, K,  et al. 1989Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.Cancer Res4910671070Google Scholar
  26. Hasui, Y, Marutsuka, K Nishi S,  et al. 1994The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer.J Urol1511620Google Scholar
  27. Dickinson AJ, Savage PB, Newcomb PV et al. The expression of urokinase, its receptor and plasminogen activator inhibitor- 1 in bladder cancer [abstract]. J Urol 1995; 153: 406A.Google Scholar
  28. Reznikoff, CA, Blair, CD, Yeager, TR,  et al. 1996A molecular genetic model of human bladder cancer pathogenesis.Semin In Oncol23571584Google Scholar
  29. Hsu, SM, Raine, L, Fanger, H 1981Use of avidinbiotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures.J Histochem Cytochem29577580PubMedGoogle Scholar
  30. M’Liss, A, Michelle, M 1997Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.J Nat Cancer Inst89(10), 21709730Google Scholar
  31. Blackburn, EH 1991Structure and function of telomeres.Nature350569573CrossRefGoogle Scholar
  32. Tabor, MW, Coats, E, Sainsbury, M,  et al. 1991Antioxidation potential of indole compounds–structure activity studies.Adv Exp Med Biol283833836Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Attalla Farag El-kott
    • 1
  • Abdalla Mohamed Khalil
    • 1
  • Ayman EL-Meghawry EL-Kenawy
    • 2
  1. 1.Urology and Nephrology CenterMansoura UniversityMansouraEqypt
  2. 2.Genetic Engineering and Biotechnology InstituteMenoufiya UniversityMenoufiyaEqypt

Personalised recommendations